EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Calcitriol supplementation after kidney transplantation: results of a double-blinded, randomized, placebo-controlled trial

Pascale Khairallah iD, Natalia E Cortez, Donald J McMahon, Stephen Sammons, Sanchita Agarwal iD, R John Crew, David J Cohen, Geoffrey K Dube, Sumit Mohan, Jae-Hyung Chang, Heather K Morris, Hilda E Fernandez und 10 weitere

Journal of Bone and Mineral Research · 2025

DOI: 10.1093/jbmr/zjaf044 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Bone and Mineral Research, 2025. Verfasst von Pascale Khairallah und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California, San Francisco, CA, 94110, United States. Hauptthemen laut MEDLINE: Kidney Transplantation, Calcitriol, Dietary Supplements. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Columbia University Vagelos College of Physicians and Surgeons, EMBO Postdoctoral Fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A significant number of kidney transplant recipients have low BMD. We hypothesized that calcitriol administration over the first year posttransplantation would protect the cortical skeleton in recipients managed without corticosteroids by suppressing PTH and bone remodeling. In this double-blind, placebo-controlled trial, 67 participants aged ≥18 yr on corticosteroid-sparing immunosuppressive regimen were randomized to daily calcitriol 0.5 μg or placebo for 12 mo after transplantation. The primary endpoint was the percent change in cortical density at the radius and tibia from pre- to postcalcitriol treatment compared to placebo as measured by HR-pQCT. Areal BMD was measured by DXA. Cortical and trabecular volumetric BMD and microarchitecture and total estimated bone strength were measured by HR-pQCT. Blood samples for bone metabolic markers were obtained at baseline, 1- and 12 mo. All primary analyses were intent to treat. Safety was assessed for hypercalcemia and progression of vascular calcifications. Thirty-two participants received calcitriol and 29 received placebo; 27 and 27 participants completed the study, respectively. Most participants were male and Caucasian. Baseline Z-scores at all sites were within 0.5 SD of the general population. At 12 mo posttransplantation, there were no between-group differences in areal BMD, volumetric BMD, microarchitecture or bone strength, or serum levels of bone markers. Participants with versus without bone loss had a blunted anabolic response over 12 mo measured by serum bone markers. Hypercalcemia was higher in the calcitriol group compared to placebo (p < .001). No changes in arterial calcification scores were observed. In this randomized placebo-controlled study of calcitriol administration in kidney transplant recipients on corticosteroid-sparing immunosuppression, calcitriol did not improve bone quality and strength but was associated with higher rates of hypercalcemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationCalcitriolDietary SupplementsHumansMaleFemaleDouble-Blind MethodMiddle AgedAdultBone DensityPlacebosAged

Stichwörter der Autor:innen

bone densitycalcitriolosteoporosistransplanttrial

Substanzen

CalcitriolPlacebos

Autor:innen und Institutionen

  • Department of Medicine, University of California, San Francisco, CA, 94110, United States.
  • Department of Clinical and Biological Sciences, University of Turin, Turin, 10124, Italy.
  • Department of Medicine, Columbia University, New York, NY, 10032, United States.
  • Department of Internal Medicine, Division of Nephrology and Hypertension, University of Utah, Salt Lake City, UT, 84112, United States.
  • CUNY School of Medicine, New York, NY, 10032, United States.
  • Independent Researcher, Padua, 35122, Italy.

ORCID-Profile: Pascale Khairallah, Sanchita Agarwal, Thomas L Nickolas

Förderung

  • NIDDK NIH HHS
  • Columbia University Vagelos College of Physicians and Surgeons
  • EMBO Postdoctoral Fellowship
  • NIH National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Khairallah, P., Cortez, N. E., McMahon, D. J., Sammons, S., Agarwal, S., Crew, R. J., Cohen, D. J., Dube, G. K., Mohan, S., Chang, J. H., Morris, H. K., Fernandez, H. E., Aponte, M. A., Adebayo, A. O., Aghi, A., Zaninotto, M., Plebani, M., Tripepi, G., Gallieni, M., …, & Nickolas, T. L. (2025). Calcitriol supplementation after kidney transplantation: results of a double-blinded, randomized, placebo-controlled trial. Journal of Bone and Mineral Research. https://doi.org/10.1093/jbmr/zjaf044

Vancouver

Khairallah P, Cortez NE, McMahon DJ, Sammons S, Agarwal S, Crew RJ, et al. Calcitriol supplementation after kidney transplantation: results of a double-blinded, randomized, placebo-controlled trial. Journal of Bone and Mineral Research. 2025. doi:10.1093/jbmr/zjaf044

BibTeX
@article{Khairallah2025,
  author = {Khairallah, Pascale and Cortez, Natalia E and McMahon, Donald J and Sammons, Stephen and Agarwal, Sanchita and Crew, R John and Cohen, David J and Dube, Geoffrey K and Mohan, Sumit and Chang, Jae-Hyung and Morris, Heather K and Fernandez, Hilda E and Aponte, Maria Alejandra and Adebayo, Aderemi O and Aghi, Andrea and Zaninotto, Martina and Plebani, Mario and Tripepi, Giovanni and Gallieni, Maurizio and Cosma, Chiara and Fusaro, Maria and Nickolas, Thomas L},
  title = {Calcitriol supplementation after kidney transplantation: results of a double-blinded, randomized, placebo-controlled trial},
  journal = {Journal of Bone and Mineral Research},
  year = {2025},
  doi = {10.1093/jbmr/zjaf044}
}
Kostenlos starten →